Literature DB >> 21463026

Clozapine and PD149163 elevate prepulse inhibition in Brown Norway rats.

David Feifel1, Paul D Shilling, Gilia Melendez.   

Abstract

Unmedicated schizophrenia patients exhibit deficits in prepulse inhibition (PPI) of the acoustic startle response. Similar deficits can be induced in rodents via a variety of manipulations and these deficits can be reversed by antipsychotics. Brown Norway (BN) rats exhibit natural PPI deficits under certain parametric conditions. We treated BN rats with haloperidol or clozapine to determine if the BN rat is a useful animal model with predictive validity for the effects of antipsychotics. In addition, we also tested PD149163, a neurotensin-1 receptor agonist, which has been shown to exhibit antipsychotic-like effects in several other animal models. BN rats received subcutaneous injections of either saline or one of two doses of haloperidol (0.5 mg/kg, 1.0 mg/kg), clozapine (7.5 mg/kg, 10 mg/kg) or PD149163 (1.0 mg/kg, 2.0 mg/kg). PPI was measured in startle chambers 30 min after injection. Systemic clozapine and PD149163 but not haloperidol facilitated PPI in BN rats (p < .001). This drug response profile suggests that the BN rat may be useful for detecting atypical antipsychotics and antipsychotics with novel mechanisms of action. The results also add to the evidence suggesting that PD149163 may have antipsychotic properties. (PsycINFO Database Record (c) 2011 APA, all rights reserved).

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21463026      PMCID: PMC3079344          DOI: 10.1037/a0022691

Source DB:  PubMed          Journal:  Behav Neurosci        ISSN: 0735-7044            Impact factor:   1.912


  28 in total

1.  Effects of a neurotensin analogue (PD149163) and antagonist (SR142948A) on the scopolamine-induced deficits in a novel object discrimination task.

Authors:  Norazrina Azmi; Christine Norman; Clare H Spicer; Geoffrey W Bennett
Journal:  Behav Pharmacol       Date:  2006-06       Impact factor: 2.293

2.  Effects of a typical and an atypical antipsychotic on the disruption of prepulse inhibition caused by corticotropin-releasing factor and by rat strain.

Authors:  Lisa H Conti; Jennifer E Costill; Sean Flynn; Jane E Tayler
Journal:  Behav Neurosci       Date:  2005-08       Impact factor: 1.912

3.  Circadian time does not modify the prepulse inhibition response or its attenuation by apomorphine.

Authors:  I C Weiss; J Feldon; A M Domeney
Journal:  Pharmacol Biochem Behav       Date:  1999-11       Impact factor: 3.533

4.  Latent inhibition and conditioning in rat strains which show differential prepulse inhibition.

Authors:  L H Conti; A A Palmer; J J Vanella; M P Printz
Journal:  Behav Genet       Date:  2001-05       Impact factor: 2.805

5.  Vasopressin-deficient rats exhibit sensorimotor gating deficits that are reversed by subchronic haloperidol.

Authors:  D Feifel; K Priebe
Journal:  Biol Psychiatry       Date:  2001-09-15       Impact factor: 13.382

Review 6.  Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review.

Authors:  M A Geyer; K Krebs-Thomson; D L Braff; N R Swerdlow
Journal:  Psychopharmacology (Berl)       Date:  2001-07       Impact factor: 4.530

Review 7.  Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies.

Authors:  D L Braff; M A Geyer; N R Swerdlow
Journal:  Psychopharmacology (Berl)       Date:  2001-07       Impact factor: 4.530

8.  Neurotensin agonists block the prepulse inhibition deficits produced by a 5-HT2A and an alpha1 agonist.

Authors:  P D Shilling; G Melendez; K Priebe; E Richelson; D Feifel
Journal:  Psychopharmacology (Berl)       Date:  2004-09       Impact factor: 4.530

9.  Antipsychotic effects on prepulse inhibition in normal 'low gating' humans and rats.

Authors:  Neal R Swerdlow; Jo Talledo; Ashley N Sutherland; Derek Nagy; Jody M Shoemaker
Journal:  Neuropsychopharmacology       Date:  2006-02-08       Impact factor: 7.853

10.  The effects of chronic administration of established and putative antipsychotics on natural prepulse inhibition deficits in Brattleboro rats.

Authors:  David Feifel; Gilia Melendez; Kristianne Priebe; Paul D Shilling
Journal:  Behav Brain Res       Date:  2007-05-01       Impact factor: 3.332

View more
  9 in total

1.  Different interactions of prolyl oligopeptidase and neurotensin in dopaminergic function of the rat nigrostriatal and mesolimbic pathways.

Authors:  I Peltonen; T T Myöhänen; P T Männistö
Journal:  Neurochem Res       Date:  2012-06-23       Impact factor: 3.996

2.  Oxytocin in schizophrenia: a review of evidence for its therapeutic effects.

Authors:  Kai Macdonald; David Feifel
Journal:  Acta Neuropsychiatr       Date:  2011-12-19       Impact factor: 3.403

3.  The effects of oxytocin and its analog, carbetocin, on genetic deficits in sensorimotor gating.

Authors:  David Feifel; Paul D Shilling; Annabelle M Belcher
Journal:  Eur Neuropsychopharmacol       Date:  2011-10-01       Impact factor: 4.600

4.  Repeated effects of the neurotensin receptor agonist PD149163 in three animal tests of antipsychotic activity: assessing for tolerance and cross-tolerance to clozapine.

Authors:  Shinnyi Chou; Collin Davis; Sean Jones; Ming Li
Journal:  Pharmacol Biochem Behav       Date:  2014-11-26       Impact factor: 3.533

5.  Effects of the neurotensin NTS₁ receptor agonist PD149163 on visual signal detection in rats.

Authors:  Todd M Hillhouse; Adam J Prus
Journal:  Eur J Pharmacol       Date:  2013-09-25       Impact factor: 4.432

Review 6.  A Review of Oxytocin's Effects on the Positive, Negative, and Cognitive Domains of Schizophrenia.

Authors:  David Feifel; Paul D Shilling; Kai MacDonald
Journal:  Biol Psychiatry       Date:  2015-08-13       Impact factor: 13.382

7.  Systemic administration of the neurotensin NTS₁-receptor agonist PD149163 improves performance on a memory task in naturally deficient male brown Norway rats.

Authors:  Ashley A Keiser; Katelin S Matazel; Melissa K Esser; David Feifel; Adam J Prus
Journal:  Exp Clin Psychopharmacol       Date:  2014-09-15       Impact factor: 3.157

Review 8.  A Role for Oxytocin in the Etiology and Treatment of Schizophrenia.

Authors:  Megan Elizabeth Rich; Heather Kingsley Caldwell
Journal:  Front Endocrinol (Lausanne)       Date:  2015-06-03       Impact factor: 5.555

9.  Clozapine N-Oxide Administration Produces Behavioral Effects in Long-Evans Rats: Implications for Designing DREADD Experiments.

Authors:  Duncan A A MacLaren; Richard W Browne; Jessica K Shaw; Sandhya Krishnan Radhakrishnan; Prachi Khare; Rodrigo A España; Stewart D Clark
Journal:  eNeuro       Date:  2016-11-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.